Effects of chemoimmunotherapy with and without surgery in murine MBT-2 bladder tumor. 1994

T S Tzai, and J S Lin, and N H Chow
Department of Urology, Medical College, National Cheng Kung University, Tainan, Taiwan, Republic of China.

Using C3H/He JCr mice bearing the syngeneic MBT-2 bladder tumor, it was found that cyclophosphamide (CYC 100 mg/kg i.p.) treatment, 1 day before and 2 weeks after surgery, followed by postoperative autologous tumor vaccine immunization can be an effective adjuvant anticancer therapy. The short-term exogeneous addition of low dose Il-2 administration to the protocol provided no further benefit. Suppression of tumor growth was observed in a classical Winn assay when splenocytes were obtained on day 23 from mice receiving this effective adjuvant therapy with surgery on day 8. Splenocytes from tumor-bearing mice (TBM) treated with CYC were augmented in terms of their proliferative response to concanavalin A during the first 2 weeks after CYC treatment. Studies using 3-day TBM established that significant suppression of tumor growth and prolonged survivals were dependent upon CYC treatment being combined with tumor vaccine and/or interleukin-2; single agent treatments were ineffective.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

T S Tzai, and J S Lin, and N H Chow
January 1997, Urological research,
T S Tzai, and J S Lin, and N H Chow
March 1994, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
T S Tzai, and J S Lin, and N H Chow
April 1988, Hinyokika kiyo. Acta urologica Japonica,
T S Tzai, and J S Lin, and N H Chow
March 1992, Hinyokika kiyo. Acta urologica Japonica,
T S Tzai, and J S Lin, and N H Chow
January 2004, Anticancer research,
T S Tzai, and J S Lin, and N H Chow
November 2004, Archives of pharmacal research,
T S Tzai, and J S Lin, and N H Chow
November 1981, Investigative urology,
T S Tzai, and J S Lin, and N H Chow
March 1983, Urology,
T S Tzai, and J S Lin, and N H Chow
January 1989, Urological research,
Copied contents to your clipboard!